

SAMPLING OF UNIVERSITY PATENT LICENSING PROGRAMS

<u>Inventor</u>	<u>University</u>	<u>Invention</u>	<u>Licensee</u>	<u>Approximate Investment</u>
Chas. Heidelberger	Wisconsin	Use of F ₃ TDR for Herpes Infections of the Eye	Burroughs Wellcome Co., Research Triangle Park, N.C.	Approx. \$5,000,000 NDA expected by end of 1977
Charles Fox	Columbia Univ.	Silver Sulfadiazine used in treatment of burns	Marion Labs., Kansas City, Mo.	Now on market - Approx. \$5,000,000
R. Fischell	Johns Hopkins	Rechargeable Cardiac Pacemaker	Pacesetter Systems Sylmar, Calif.	On market since Feb. 1975 - Approx. \$720,000
Monte Holland	Tulane Univ.	Method of Reducing Intraocular Pressure in the Human Eyes	Cooper Labs., Bedford Hills, N.Y.	\$2,000,000 - Development leading to DNA is in process and on schedule
Berton Pressman	Univ. of Miami	Application of X-537A in the Cardiovascular System (for stimulation in cardiogenic shock, congestive heart failure, etc.)	Hoffmann-LaRoche, Nutley, N.J.	\$500,000 to \$1,000,000 Clinical evaluations still in progress
Willard Higley	Natl. Institute of Scientific Research	Polycarbonate Dialysis Membranes	C.R. Bard, Inc., Murray Hill, N.J.	Over \$1,000,000. Market introduction expected imminently
Talbot/Harrison	Johns Hopkins	Ballistocardiograph apparatus	Royal Medical Corp. Huntsville, Ala.	Approx. \$330,000. Now on market
Stanley Plotkin	Wistar Institute	Rubella Vaccine	1) Wellcome Foundation 2) L'Institut Merieux 3) Swiss Serum and Vaccine Institute and others (Merck, an Italian firm, etc.)	Approx. millions - Now on market -

SAMPLING OF UNIVERSITY PATENT LICENSING PROGRAMS

<u>Inventor</u>	<u>University</u>	<u>Invention</u>	<u>Licensee</u>	<u>Approximate Investment</u>
McKensie Walzer	Johns Hopkins	Keto-Acid analogs of Amino Acids for treatment of uremia	Pfrimmer of Germany and Syntex of U.S.A.	Millions - Clinical trials in process. Expected to be marketed in 6 mos. in Europe
Tadeusz J. Wiktor	Wistar Institute	Rabies Vaccine	Wyeth Laboratories	On the market - millions
Barton Kamen et al	Case Western Res.	Methotrexate Assay	Diamond Shamrock Corp.	Being test-marketed. Production scheduled for late 1977. Millions.
Lillehei/Kaster	Univ. of Minnesota	Pivoting Disc Heart Valve	Medical, Inc.	Being sold in world-wide market since 1971. Millions
Blackshear et al	Univ. of Minnesota	Implantable Infusion Pump	Metal Bellows Co.	Undergoing clinical trials. \$750,000.
DeLuca	Univ. of Wisconsin	25-Hydroxycholecalciferol	Rousel-Uclaf (Hoechst)	Have applied for equivalent of NDA in France. Approximately \$5 million.
			Upjohn	About to apply for an NDA and an NADA. Will spend about \$10 million.
DeLuca	Univ. of Wisconsin	1-Alpha Hydroxycholecalciferol	Leo Pharmaceuticals	Applying for new drug applications in Denmark and Great Britain. May be marketed this year. Approx. \$5,000,000.
DeLuca et al	Univ. of Wisconsin	1, 25-Dehydroxyergocalciferol	Hoffman-LaRoche Inc.	About to apply for NDA. Will spend about \$10 million.

SAMPLING OF UNIVERSITY PATENT LICENSING PROGRAMS

<u>Inventor</u>	<u>University</u>	<u>Invention</u>	<u>Licensee</u>	<u>Approximate Investment</u>
Josef Fried	Univ. of Chicago	Prostaglandins	Richardson-Merrell, New York, N.Y.	Several millions. In process of develop- ment and testing for marketing here and abroad.